Ubiquitin-activating enzyme (E1) inhibitor; prevents tumour suppressor protein p27 ubiquitination in vitro. Blocks the ubiquitin-thioester formation step of the E1 activation reaction, but displays no effect on ubiquitin adenylation.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 410.51. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.44 mL||12.18 mL||24.36 mL|
|5 mM||0.49 mL||2.44 mL||4.87 mL|
|10 mM||0.24 mL||1.22 mL||2.44 mL|
|50 mM||0.05 mL||0.24 mL||0.49 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Ungermannova et al (2012) Identification and mechanistic studies of a novel ubiquitin E1 inhibitor. J.Biomol.Screen. 17 421 PMID: 22274912
If you know of a relevant reference for NSC 624206, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: NSC 624206, supplier, NSC624206, tumour, suppressor, protein, p27, ubiquitination, thioesterformation, adenylation, ubiquitin-activating, enzymes, E1, inhibitors, inhibits, Ubiquitin-activating, Enzyme, E1, Tocris Bioscience
Citations for NSC 624206
Citations are publications that use Tocris products.
Currently there are no citations for NSC 624206. Do you know of a great paper that uses NSC 624206 from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.